San Diego, CA Clinical Trials Report — June 2026

San Diego residents looking to contribute to medical research have a significant window of opportunity this June, with a total of 706 clinical trials currently recruiting across 339 local research facilities. For those ready to act, 36 trials are slated to close within the next 90 days, making prompt participation crucial for interested individuals.

Among these rapidly concluding studies, 6 trials are specifically seeking healthy volunteers, offering a chance to contribute to science without a pre-existing condition before their enrollment periods end. This presents an immediate opportunity for individuals eager to support medical advancements.

Urgent Opportunities: Trials Closing Soon

Patients with specific health conditions should also note trials nearing their enrollment deadlines. Conditions with trials closing soon include:

• Cancer (2 trials)
• Acute liver injury (1 trial)
• Basal cell carcinoma (1 trial)
• Alcohol use disorder (1 trial)
• Amyotrophic lateral sclerosis (1 trial)
• Atopic dermatitis (1 trial)
• Advanced solid tumor (1 trial)
• Behavioral variant frontotemporal dementia (bvftd) (1 trial)
• Bladder cancer (1 trial)
• Bladder pain syndrome (1 trial)

New Research Horizons in San Diego

This month brings fresh opportunities, with 16 new trials opening in San Diego, a slight increase from the 14 that launched in May 2026. These new studies span various health areas, with a notable focus on metabolic and pain management conditions.

New trials are exploring conditions such as overweight (3 trials), obesity (3 trials), chronic pain (3 trials), and chronic weight management (2 trials). Other conditions include help seeking, hematuria, implementation research, low back pain, major depressive disorder (MDD), and major depressive episode (MDE). The majority of these new studies are drug trials, with 11 focusing on new medications, alongside 2 device trials and 1 behavioral study.

Notable New Trials from Major Sponsors

Several major sponsors have launched significant Phase 3 drug trials in San Diego this month, offering participants access to cutting-edge research:

• Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics is initiating a pivotal Phase 3 study, NCT07654361, "Efficacy and Safety of Aleniglipron in Participants With Obesity or Overweight With a Weight-Related Comorbidity (ACCOMPLISH-1)." This global, randomized, placebo-controlled, double-blind study aims for 3,600 participants to investigate the long-term efficacy, safety, and tolerability of aleniglipron once daily.
• Also from Gasherbrum Bio, Inc., NCT07654374, "A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)," is a Phase 3 randomized, double-blind, placebo-controlled study involving 1,100 participants to evaluate aleniglipron's efficacy, safety, and tolerability in those with overweight or obesity and Type 2 Diabetes Mellitus.
• Kallyope Inc. is sponsoring NCT07645924, "A Study to Evaluate the Efficacy and Safety of Elismetrep (K-304) in the Acute Treatment of Migraine." This Phase 3 double-blind, randomized, multicenter trial seeks 1,800 participants to assess the efficacy, safety, and tolerability of elismetrep compared with placebo.
• Another study from Kallyope Inc. is NCT07674654, "A Long-Term Safety Study of Elismetrep (K-304) in the Acute Treatment of Migraine." This Phase 3 study aims for 1,000 participants to evaluate the long-term safety and tolerability of intermittent elismetrep use.
• AstraZeneca has launched NCT07662044, "A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Alone or in Combination With Dapagliflozin Compared With Placebo in Adults With Type 2 Diabetes Mellitus." This Phase 3 study with 800 participants will evaluate elecoglipron's efficacy, safety, and tolerability in adults with inadequately managed Type 2 Diabetes Mellitus.
• Convergent Genomics, Inc. is leading NCT07673016, "Specimen Collection for Validation of UroAmp: A Next Generation Sequencing Platform for Detection and Surveillance of Bladder Cancer." This observational study aims to collect urine and tumor biospecimens from 2,500 patients for bladder cancer detection and surveillance.

Opportunities for Healthy Volunteers

For individuals without a specific medical condition, there are significant opportunities to contribute to research. Of the 16 new trials launched this month, 2 are actively seeking healthy volunteers. Across San Diego, a total of 89 clinical trials are currently recruiting healthy participants, providing numerous avenues for those interested in supporting medical research.

San Diego's Leading Research Facilities

San Diego's vibrant research ecosystem is driven by several leading institutions, which consistently host a high volume of clinical trials. These facilities are key destinations for individuals seeking to participate in medical research:

• University of California San Diego (37 trials)
• University of California, San Diego (37 trials)
• Rady Children's Hospital - San Diego (33 trials)
• Rady Children's Hospital (31 trials)
• UC San Diego Medical Center - Hillcrest (24 trials)
• Research Site (22 trials)
• Kaiser Permanente-San Diego Zion (21 trials)
• VA San Diego Healthcare System, San Diego, CA (20 trials)
• San Diego State University (17 trials)
• Rady Children's Hospital San Diego (14 trials)

The University of California San Diego and Rady Children's Hospital, through their various affiliated sites, collectively lead the city in trial volume, offering a broad spectrum of research opportunities across diverse medical fields.

Broadening Your Search: Nearby Options

While San Diego offers extensive opportunities, residents in California may also consider trials in nearby cities. Other locations with active trials include Los Angeles (31 trials), San Francisco (17 trials), Palo Alto (10 trials), and even within the San Diego region, La Jolla (9 trials). Further options are available in Stanford (7 trials), Sacramento (6 trials), Duarte (6 trials), and Walnut Creek (6 trials).

Participation in San Diego's clinical trials is inclusive, with 14 of the new trials accepting older adults and 3 including children. This ensures a broad demographic can contribute to advancing healthcare. Industry sponsors, including Eli Lilly and Company, Gasherbrum Bio, Inc., and Kallyope Inc., are driving a significant portion of new research this month, alongside academic institutions like the University of California, San Diego.

As June progresses, San Diego's commitment to clinical research continues to grow, offering diverse and impactful ways for patients and healthy volunteers alike to shape the future of medicine.